The trial will see healthy volunteers infected with dengue to test the impact of AbViro’s monoclonal antibody therapy.

Takeda Healthcare Philippines, Inc. and Otsuka-Solar Philippines, Inc., with the support of the Embassy of Japan in the Ph ...

Introduction State of the Art Dengue Vaccine Development Challenges ... vaccine based on DENV2-PDK-53 CDC/Inviragen/Takeda Phase II Live-attenuated vaccine based on DEN4Δ30 NIAID, NIH/BUTANTAN ...

The illness typically lasts two to seven days, but severe cases can be deadly. An affected person will have flu-like symptoms ...

Takeda had hoped that Eohilia would be the ... The drugmaker has had mixed results from Wave1, with approvals for dengue fever vaccine Qdenga and post-transplant cytomegalovirus (CMV) therapy ...

Takeda has had a run of bad luck with ... its live attenuated tetravalent vaccine for prevention of dengue disease. Near-term attention now shifts to maribavir for cytomegalovirus infections ...

the same vectors that spread dengue and zika. The broad-based agreement includes early stage development to the final commercialisation of the vaccine. There is currently no vaccine to prevent or ...

The NIH announced that it is launching a phase 2 human challenge trial of AV-1, an investigational monoclonal antibody to ...

Researchers have unveiled new insights into how weather influences the spread of dengue fever. Their study identifies ...

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help people suffering the effects of dengue, a mosquito-borne viral disease.